Severe Aplastic Anemia Clinical Trial
Official title:
Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired Severe Aplastic Aplasia Receiving Single Cord Blood Transplant: A Multi-center, Single-arm Study
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of acquired Severe Aplastic Anemia (SAA).
Hematopoietic stem cell transplantation (HSCT) from HLA-compatible sibling donors is the standard preferred therapy for Severe Aplastic Anemia (SAA). At present, HLA-compatible donors in China fail to meet the needs of patients for transplantation. Umbilical Cord blood transplantation (UCBT) is an alternative treatment for patients with emergency conditions who lack compatible sibling donors, have failed immunosuppressant therapies or cannot wait for unrelated fully compatible donors. However, implantation failure is one of the main problems in UCBT for SAA due to the low cord blood stem cells. Nowadays, there is no consensus on the optimal conditioning regimen for UCBT treatment of SAA, and whether ATG should be added to the conditioning regimen is still controversial. Early clinical studies in UCBT have shown that the sufficient ATG in the conditioning regimen will lead to a decrease rate of implantation rate and affect survival of UCBT ultimately. However, a range of recent studies have found that with the addition of low-dose ATG, T cell reconstitution seems to outperform bone marrow or peripheral blood stem cell transplantation. Therefore, how to properly use ATG to both retain its effective GVHD prevention effect and reduce its impact on immune reconstruction has important clinical significance for improving the transplantation efficacy. In this study, a multicenter clinical study will be conducted to observe the safety and efficacy of UCBT with low dose ATG in the treatment of SAA and the long-term quality of life of patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02828592 -
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
|
Phase 2 | |
| Completed |
NCT02833805 -
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
|
Phase 2 | |
| Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
| Recruiting |
NCT05012111 -
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
|
||
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Enrolling by invitation |
NCT05049668 -
RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
|
||
| Recruiting |
NCT01472055 -
Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT01351545 -
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
|
||
| Completed |
NCT01703169 -
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
|
Phase 2 | |
| Withdrawn |
NCT01129323 -
Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia
|
N/A | |
| Completed |
NCT00516152 -
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
|
Phase 2 | |
| Recruiting |
NCT06069180 -
The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
|
Phase 4 | |
| Recruiting |
NCT03579875 -
T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia
|
Phase 2 | |
| Recruiting |
NCT05720234 -
Avatrombopag Combined With IST as First-line Treatment for SAA
|
Phase 2 | |
| Recruiting |
NCT04304820 -
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
|
Phase 2 | |
| Terminated |
NCT00358657 -
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
|
Phase 2 | |
| Completed |
NCT02998645 -
Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
|
Phase 2 | |
| Active, not recruiting |
NCT03825744 -
Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
|
Phase 3 | |
| Not yet recruiting |
NCT06279494 -
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
|
Phase 1/Phase 2 |